Yuan Hailong, Chen Gang, Xu Jianli, Yang Ruixue, Muhashi Maria, Aizezi Gulibadanmu, Jiang Ming
Hematology Center, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology, Urumqi, China.
Front Oncol. 2022 Jul 15;12:913802. doi: 10.3389/fonc.2022.913802. eCollection 2022.
We conducted a single-center 5-year retrospective study on the occurrence of hemorrhagic cystitis (HC) and its effect on survival after haploid high-dose peripheral blood stem cell transplantation (haplo-PBSCT) in patients with acute leukemia. We retrospectively analyzed 153 patients with acute leukemia who were treated with non- T-cell depleted haplo-PBSCT and myeloablative conditioning regimen. All patients were followed up for more than 180 days after transplantation. HC occurrence and its effect on long-term progression free survival (PFS) were retrospectively analyzed. Totally, 64 out of 153 patients had late onset HC (LOHC). No early onset HC occurred. The median onset time was 38.5 (17-163) days after transplantation. The cumulative incidence of LOHC was 41.8%. The cumulative incidence of LOHC in patients under 27 years old (50.0%) and in ALL patients (54.1%) was significantly higher than that in patients over 27 years old (34.5%) and in AML patients (36.9%), respectively. The cumulative incidence of mild LOHC was 44.2% and that of severe LOHC was 28.6%. However, urine copies of BK virus were not related to LOHC duration. There was no significant difference in 3-year expected PFS between AML and ALL patients with and without LOHC, or between LOHC duration more than and less than 38.5 days (P>0.05). Conclusively, LOHC incidence is higher in patients under 27 years old and in ALL patients. LOHC occurrence is related to urine BK virus copy, but not blood BK virus load. LOHC duration and severity has no significant effect on PFS.
我们对急性白血病患者单倍体高剂量外周血干细胞移植（haplo - PBSCT）后出血性膀胱炎（HC）的发生情况及其对生存的影响进行了一项单中心5年回顾性研究。我们回顾性分析了153例接受非T细胞去除单倍体PBSCT及清髓性预处理方案治疗的急性白血病患者。所有患者在移植后均随访超过180天。对HC的发生情况及其对长期无进展生存（PFS）的影响进行了回顾性分析。153例患者中共有64例发生迟发性HC（LOHC）。未发生早发性HC。中位发病时间为移植后38.5（17 - 163）天。LOHC的累积发生率为41.8%。27岁以下患者（50.0%）和急性淋巴细胞白血病（ALL）患者（54.1%）的LOHC累积发生率分别显著高于27岁以上患者（34.5%）和急性髓细胞白血病（AML）患者（36.9%）。轻度LOHC的累积发生率为44.2%，重度LOHC的累积发生率为28.6%。然而BK病毒尿拷贝数与LOHC持续时间无关。有或无LOHC的AML和ALL患者之间，以及LOHC持续时间大于和小于38.5天的患者之间，3年预期PFS无显著差异（P>0.05）。结论是，27岁以下患者和ALL患者中LOHC发生率较高。LOHC的发生与尿BK病毒拷贝数有关，但与血BK病毒载量无关。LOHC持续时间和严重程度对PFS无显著影响。
